NeuroPace IncNPCEEarnings & Financial Report
NeuroPace Inc is a medical technology company focused on developing and commercializing innovative implantable neurostimulation systems to treat neurological disorders, primarily drug-resistant epilepsy. Its core RNS System delivers personalized responsive stimulation to reduce seizure frequency, serving patients across North America and select global markets via partnerships with healthcare providers.
Revenue
$21.1M
Gross Profit
$15.4M
Operating Profit
$-4.2M
Net Profit
$-5.5M
Gross Margin
73.2%
Operating Margin
-20.1%
Net Margin
-25.9%
YoY Growth
28.2%
EPS
$-0.19
NeuroPace Inc Q3 FY2024 Financial Summary
NeuroPace Inc reported revenue of $21.1M (up 28.2% YoY) for Q3 FY2024, with a net profit of $-5.5M (up 24.9% YoY) (-25.9% margin). Cost of goods sold was $5.6M, operating expenses totaled $19.7M.
Key Financial Metrics
| Total Revenue | $21.1M |
|---|---|
| Net Profit | $-5.5M |
| Gross Margin | 73.2% |
| Operating Margin | -20.1% |
| Report Period | Q3 FY2024 |
NeuroPace Inc Annual Revenue by Year
NeuroPace Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $100.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $100.0M |
| 2024 | $79.9M |
| 2023 | $65.4M |
| 2022 | $45.5M |
NeuroPace Inc Quarterly Revenue & Net Profit History
NeuroPace Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.6M | +23.9% | $-2.7M | -10.3% |
| Q3 FY2025 | $27.4M | +29.9% | $-3.5M | -12.8% |
| Q2 FY2025 | $23.5M | +22.1% | $-8.7M | -36.8% |
| Q1 FY2025 | $22.5M | +24.3% | $-6.6M | -29.3% |
| Q4 FY2024 | $21.5M | +19.2% | $-5.3M | -24.5% |
| Q3 FY2024 | $21.1M | +28.2% | $-5.5M | -25.9% |
| Q2 FY2024 | $19.3M | +16.6% | $-7.5M | -39.0% |
| Q1 FY2024 | $18.1M | +25.2% | $-8.9M | -49.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.1M | $19.3M | $21.1M | $21.5M | $22.5M | $23.5M | $27.4M | $26.6M |
| YoY Growth | 25.2% | 16.6% | 28.2% | 19.2% | 24.3% | 22.1% | 29.9% | 23.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $98.9M | $94.4M | $96.3M | $94.6M | $110.2M | $106.1M | $107.3M | $105.6M |
| Liabilities | $84.5M | $84.5M | $86.5M | $86.6M | $85.9M | $86.7M | $88.7M | $86.5M |
| Equity | $14.3M | $9.9M | $9.8M | $8.0M | $24.3M | $19.4M | $18.5M | $19.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.5M | $-3.9M | $-1.7M | $-4.8M | $-7.5M | $-2.1M | $-1.9M | $506000 |